Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 12/20 | 0.41 |
| ▸ | HRH2 | P25021 | 6/20 | 0.41 |
| ▸ | HTR2A | P28223 | 4/20 | 0.37 |
| ▸ | HTR2C | P28335 | 4/20 | 0.37 |
| ▸ | HTR2B | P41595 | 4/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12891717 | 1.00 | HRH3 (0.41) | HRH3HRH2HTR2AHTR2CHTR2B | |
| SCHEMBL30708688 | 0.89 | HTR2C (0.39) | HRH3HRH2HTR2AHTR2CHTR2B | |
| SCHEMBL19130936 | 0.89 | HTR2C (0.39) | HRH3HRH2HTR2AHTR2CHTR2B | |
| SCHEMBL30002078 | 0.79 | IRAK4 (0.37) | HTR2AHTR2CHTR2BKCNH2HDAC1 | |
| SCHEMBL868218 | 0.79 | ACHE (0.41) | HTR2AHTR2CHTR2BKCNH2HDAC1 | |
| SCHEMBL10287316 | 0.79 | ACHE (0.41) | HTR2AHTR2CHTR2BKCNH2HDAC1 | |
| SCHEMBL12993345 | 0.79 | HTR2A (0.36) | HRH3HTR2AHTR2CHTR2BKCNH2 | |
| SCHEMBL2303573 | 0.79 | IRAK4 (0.37) | HTR2AHTR2CHTR2BKCNH2HDAC1 | |
| SCHEMBL29814887 | 0.79 | ACHE (0.41) | HTR2AHTR2CHTR2BKCNH2HDAC1 | |
| SCHEMBL14884980 | 0.79 | ACHE (0.41) | HTR2AHTR2CHTR2BKCNH2HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7880009-B2 | Alzheimer's disease, senile dementia, Down syndrome or amyloidosis; (E)-N-biphenyl-3-ylmethyl-3-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)acrylamide for example; imidazolyl-functional compounds inhibit production of Amyloid beta 40 and Amyloid beta 42 | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-02-01 | — | — | US | disclosed |
| EP-2261218-A2 | Process for preparing phenyl-, pyridinyl- or pyrimidinyl-substituted imidazoles | Eisai R&D Management Co., Ltd. (JP) | 2010-12-15 | — | — | EP | disclosed |
| US-7687640-B2 | Cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-03-30 | — | — | US | disclosed |
| US-20090281310-A1 | 3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzaldehyde; inhibits production of A beta 40 and A beta 42 from amyloid precursor protein ; Alzheimer's disease and Down syndrome | EISAI R&D MANAGEMENT CO., LTD. | 2009-11-12 | — | — | US | disclosed |
| US-20080070902-A1 | Cinnamide Compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281310-A1 | 3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzaldehyde; inhibits production of A beta 40 and A beta 42 from amyloid precursor protein ; Alzheimer's disease and Down syndrome | APP, PSEN1, BACE1 | HRH3 3778/4885HRH2 4192/4885HTR2A 373/4885 |
| US-20080070902-A1 | Cinnamide Compound | C1S, CCR1, CNR1 | HRH3 253/4885HRH2 238/4885HTR2A 2182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.